Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

OncoKey™ SL 60 Plus Assay

Luye Group
Laboratory Developed Test
Related tests:


Vela Diagnostics launches focused (60 genes) and comprehensive (525 genes) NGS-based pan-cancer panels (VelaDx Press Release)
"Vela Diagnostics announced today the launch of its new OncoKey® SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run."
OncoKey™ SL 525 Plus Assay • OncoKey™ SL 60 Plus Assay
[VIRTUAL] A Next-Generation Sequencing Assay for Comprehensive Genomic Profiling and Identification of Microbial Signatures in Tumor Samples (AMP 2020)
Robust automation coupled with a sensitive and accurate UMI-based hybridization capture workflow, we demonstrate that the OncoKey SL60 and 525 Plus assays can rapidly identify clinically relevant DNA and RNA variants in FFPE samples, as well as the microbial signatures in various tumor types.
Next-generation sequencing
OncoKey™ SL 60 Plus Assay